Johns Hopkins University led the U.S. in higher education research spending for the 35th consecutive year in fiscal 2013, with $2.2 billion for medical, science, and engineering research, according to the National Science Foundation.
The university also once again ranked first on the NSF’s separate list of federally funded research and development, spending $1.89 billion in fiscal year 2013 on research supported by NSF, NASA, the National Institutes of Health, and the Department of Defense.
BioHealth Innovation, Inc. (BHI), a public-private partnership and innovation intermediary is seeking an energetic and motivated life science professional for the role of an Entrepreneur-In-Residence (EIR) with product development experience and subject matter expertise in the fields of neurology and neuroscience. The EIR will reside within the National Institutes of Health (NIH) and will also support intramural and extramural initiatives on an as needed basis.
The EIR program was established at BioHealth Innovation to:
The EIR will work with BHI leadership to ensure that the activities and outcomes are aligned with BHIs strategic focus.
EIR PROGRAM EXPECTATION
TECHNICAL EXPERTISE, ANALYSIS & EVALUATION
OUTREACH & PARTNERSHIPS
QUALIFICATIONS
TERMS & COMPENSATION
Compensation for this position is competitive and negotiable. BHI is an equal opportunity employer.
APPLICATION PROCEDURE
Interested applicants should send their resume and cover letter to Amanda Wilson at awilson@biohealthinnovation.org
The Mid-Atlantic Life Sciences Showcase is the new name for the ISPE-CBA Vendor Night. ISPE is continuing to improve the event and this year will not disappoint! Table selections will be made by the order in which you register. Register early to ensure your pick of locations.
Under Armour is doubling down on a big bet it made on fitness apps a year and a half ago.
On Wednesday, the company best known as an athletic apparel brand announced it was spending $475 million to buy MyFitnessPal and $85 million on Endomondo, two apps that rivaled the offerings of Under Armour’s Connected Fitness unit.
In tracking life science investors worldwide, LSN’s research team has noticed that there are a growing number of Asia-based investors seeking global opportunities as well as investments in the U.S. and Asia.
GlaxoSmithKline (GSK.L) set out a roadmap for a potential 2016 flotation of its HIV medicines business on Wednesday as it hired three leading banks to advise on what would be the drug industry’s largest ever initial public share sale.
Chief Executive Andrew Witty said his company would take the next two to three months to analyze the pros and cons of an initial public offering (IPO), as well as deciding how much of ViiV to sell and where to list the shares.
Yanev Suissa, formerly a venture capitalist with New Enterprise Associates and a senior investment officer in the Bush and Obama administrations, is launching a new venture firm with a focus on companies doing business with the public sector.
The company’s debut fund has raised around $100 million and will focus primarily on Series A and B investments with the occasional Series C, which will likely include local companies. The firm, to be named SineWave Ventures, will officially launch in the region in the second half of the year.
UMD start-up SD Nanosciences has developed technology for creating targeted drug and vaccine delivery vehicles
When University of Maryland Professors Philip DeShong and Daniel Stein began tagging soap bubbles with biomolecules, they had no idea this technology would one day be poised to change the way drugs and vaccines fight against bacteria, viruses and cancer.
Notice is hereby given that the Office of Intramural Research (OIR), National Institutes of Health (NIH), will host two webinars to enable public discussion of its proposal to reorganize the OIR Office of Technology Transfer (OTT). The proposal seeks to align authority and responsibility for the implementation and execution of patenting and licensing (P&L) functions within the NIH Institutes and Centers.
MedImmune, the global biologics research and development arm of AstraZeneca, and The University of Manchester have entered into a new research collaboration to generate cutting-edge protein formulation science.
As part of the collaboration, MedImmune will work with researchers at Manchester’s Centre of Excellence in Biopharmaceuticals (COEBP) on testing and understanding the fundamental principles of protein solution behavior in order to find better ways to administer breakthrough medicines to patients.
